Interventional, Open-label, Interaction Study Investigating the Effects of Itraconazole (Inhibitor of CYP3A4/5) on the Pharmacokinetics and Safety and Tolerability of Lu AF11167 in Healthy Young Subjects
Phase of Trial: Phase I
Latest Information Update: 22 Sep 2015
Price : $35 *
At a glance
- Drugs Lu AF11167 (Primary) ; Itraconazole
- Indications Neurodegenerative disorders; Psychotic disorders
- Focus Pharmacokinetics
- Sponsors Lundbeck A/S
- 18 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 Mar 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
- 25 Nov 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Dec 2014, according to the ClinicalTrials.gov record.